Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Feb;55(2):413-20.
doi: 10.1007/s00125-011-2376-1. Epub 2011 Nov 18.

An important minority of prediabetic first-degree relatives of type 1 diabetic patients derives from seroconversion to persistent autoantibody positivity after 10 years of age

Affiliations

An important minority of prediabetic first-degree relatives of type 1 diabetic patients derives from seroconversion to persistent autoantibody positivity after 10 years of age

I Vermeulen et al. Diabetologia. 2012 Feb.

Abstract

Aims/hypothesis: The appearance of autoantibodies (Abs) before diabetes onset has mainly been studied in young children. However, most patients develop type 1 diabetes after the age of 15 years. In first-degree relatives aged under 40 years, we investigated the frequency of seroconversion to (persistent) Ab positivity, progression to diabetes and baseline characteristics of seroconverters according to age.

Methods: Abs against insulin (IAA), glutamate decarboxylase (GADA), insulinoma-associated protein 2 (IA-2A) and zinc transporter 8 (ZnT8A) were measured during follow-up of 7,170 first-degree relatives.

Results: We identified 379 (5.3%) relatives with positivity for IAA, GADA, IA-2A and/or ZnT8A (Ab(+)) at first sampling and 224 (3.1%) at a later time point. Most seroconversions occurred after the age of 10 years (63%). During follow-up, Abs persisted more often in relatives initially Ab(+) (76%) than in seroconverters (53%; p < 0.001). In both groups diabetes developed at a similar pace and almost exclusively with Ab persistence (136 of 139 prediabetic individuals). For both groups, progression was more rapid if Abs appeared before the age of 10 years. Baseline characteristics at seroconversion did not vary significantly according to age.

Conclusions/interpretation: Seroconversion to (persistent) Ab(+) occurs regardless of age. Although the progression rate to diabetes is higher under age 10 years, later seroconverters (up to age 40 years) have similar characteristics when compared with age-matched initially Ab(+) relatives and generate an important minority of prediabetic relatives, warranting their identification and, eventually, enrolment in prevention trials.

PubMed Disclaimer

Conflict of interest statement

Duality of interest: The authors declare that there is no duality of interest associated with this manuscript.

Figures

Fig 1
Fig 1. Disposition diagram showing all participants in the present study, their antibody status and their progression to diabetes
Fig 2
Fig 2
Diabetes-free survival of persistently Ab+ relatives as a function of time after first Ab+ sample. Panel a: Ab+ relatives at baseline ( ; n = 289 at time 0) vs. seroconverters to Abpositivity ( ; n = 118 at time 0) (p = 0.505 by log-rank); panel b: Ab+ relatives at baseline according to age at inclusion ( : 0-9 years; : 10-19 years; : 20-39 years; p = 0.003 by log-rank); panel c: seroconverters to Ab-positivity according to age at seroconversion ( : 0- 9 years; : 10-19 years; : 20-39 years; p = 0.042 by log-rank)

References

    1. Leslie RD, Delli Castelli M. Age-dependent influences on the origins of autoimmune diabetes: evidence and implications. Diabetes. 2004;53:3033–3040. - PubMed
    1. Pipeleers D, Ling Z. Pancreatic beta cells in insulin-dependent diabetes. Diabetes Metab Rev. 1992;8:209–227. - PubMed
    1. Gorus FK. Diabetes registries and early biological markers of insulin-dependent diabetes mellitus. Belgian Diabetes Registry. Diabetes Metab Rev. 1997;13:247–274. - PubMed
    1. Skyler JS, Ricordi C. Stopping type 1 diabetes: attempts to prevent or cure type 1 diabetes in man. Diabetes. 2011;60:1–8. - PMC - PubMed
    1. Keymeulen B, Walter M, Mathieu C, et al. Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia. 2010;53:614–623. - PubMed

Publication types

MeSH terms